UNLABELLED: The aim of this study was to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the antivascular compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA; vadimezan). METHODS: (18)F-FMISO PET was performed 3 h before and 24 h after treatment with DMXAA (20 mg/kg) in mice bearing HT29 xenograft tumors. Pimonidazole was coadministered with the first (18)F-FMISO injection, and 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide (EF5) was coadministered with the second one. Hoechst 33342 was administered 5 min before sacrifice. Digital autoradiograms of tumor sections were acquired; this acquisition was followed by immunofluorescence microscopic visualization of pimonidazole, EF5, the Hoechst 33342, CD31, and α-smooth muscle actin. RESULTS: DMXAA treatment resulted in a marked reduction in the (18)F-FMISO mean standardized uptake value (SUV(mean)) in approximately half of the treated tumors. The reduction in SUV(mean) correlated with a decrease in the fraction of tumor area staining positive for both EF5 and pimonidazole. Compared with untreated controls, tumors with decreasing SUV(mean) had significantly fewer perfused microvessels. CONCLUSION: (18)F-FMISO PET could distinguish between different tumor responses to DMXAA treatment. However, a reduction in (18)F-FMISO SUV(mean) after DMXAA treatment was indicative of reduced perfusion and therefore delivery of (18)F-FMISO, rather than a reduction in tumor hypoxia.
UNLABELLED: The aim of this study was to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the antivascular compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA; vadimezan). METHODS: (18)F-FMISOPET was performed 3 h before and 24 h after treatment with DMXAA (20 mg/kg) in mice bearing HT29 xenograft tumors. Pimonidazole was coadministered with the first (18)F-FMISO injection, and 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide (EF5) was coadministered with the second one. Hoechst 33342 was administered 5 min before sacrifice. Digital autoradiograms of tumor sections were acquired; this acquisition was followed by immunofluorescence microscopic visualization of pimonidazole, EF5, the Hoechst 33342, CD31, and α-smooth muscle actin. RESULTS:DMXAA treatment resulted in a marked reduction in the (18)F-FMISO mean standardized uptake value (SUV(mean)) in approximately half of the treated tumors. The reduction in SUV(mean) correlated with a decrease in the fraction of tumor area staining positive for both EF5 and pimonidazole. Compared with untreated controls, tumors with decreasing SUV(mean) had significantly fewer perfused microvessels. CONCLUSION: (18)F-FMISOPET could distinguish between different tumor responses to DMXAA treatment. However, a reduction in (18)F-FMISO SUV(mean) after DMXAA treatment was indicative of reduced perfusion and therefore delivery of (18)F-FMISO, rather than a reduction in tumor hypoxia.
Authors: Mark J McKeage; Martin Reck; Michael B Jameson; Mark A Rosenthal; David Gibbs; Paul N Mainwaring; Lutz Freitag; Richard Sullivan; Joachim Von Pawel Journal: Lung Cancer Date: 2009-05-05 Impact factor: 5.705
Authors: J G Tjuvajev; N Avril; T Oku; T Sasajima; T Miyagawa; R Joshi; M Safer; B Beattie; G DiResta; F Daghighian; F Augensen; J Koutcher; J Zweit; J Humm; S M Larson; R Finn; R Blasberg Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701
Authors: Xiao-Feng Li; Sean Carlin; Muneyasu Urano; James Russell; C Clifton Ling; Joseph A O'Donoghue Journal: Cancer Res Date: 2007-08-15 Impact factor: 12.701
Authors: W J Koh; K S Bergman; J S Rasey; L M Peterson; M L Evans; M M Graham; J R Grierson; K L Lindsley; T K Lewellen; K A Krohn Journal: Int J Radiat Oncol Biol Phys Date: 1995-09-30 Impact factor: 7.038
Authors: HyungJoon Cho; Ellen Ackerstaff; Sean Carlin; Mihaela E Lupu; Ya Wang; Asif Rizwan; Joseph O'Donoghue; C Clifton Ling; John L Humm; Pat B Zanzonico; Jason A Koutcher Journal: Neoplasia Date: 2009-03 Impact factor: 5.715
Authors: Jennifer G Whisenant; Todd E Peterson; Jacob U Fluckiger; Mohammed Noor Tantawy; Gregory D Ayers; Thomas E Yankeelov Journal: Mol Imaging Biol Date: 2013-02 Impact factor: 3.488
Authors: Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin Journal: NMR Biomed Date: 2012-07-08 Impact factor: 4.044
Authors: Heling Zhou; Rami R Hallac; Ramona Lopez; Rebecca Denney; Matthew T MacDonough; Li Li; Li Liu; Edward E Graves; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason Journal: Am J Nucl Med Mol Imaging Date: 2015-01-15
Authors: Rachel M Bartlett; Bradley J Beattie; Manoj Naryanan; Jens-Christoph Georgi; Qing Chen; Sean D Carlin; Gordon Roble; Pat B Zanzonico; Mithat Gonen; Joseph O'Donoghue; Alexander Fischer; John L Humm Journal: J Nucl Med Date: 2012-08-29 Impact factor: 10.057
Authors: Chunying Wu; Xizhen Wang; Nicholas Tomko; Junqing Zhu; William R Wang; Jinle Zhu; Bin Wangf; Yanming Wang; Robert G Salomon Journal: Anticancer Agents Med Chem Date: 2017 Impact factor: 2.505
Authors: Anna G Sorace; Anum K Syed; Stephanie L Barnes; C Chad Quarles; Violeta Sanchez; Hakmook Kang; Thomas E Yankeelov Journal: Mol Imaging Biol Date: 2017-02 Impact factor: 3.488